Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers. / Johannesen, Caroline Klint; Martin, Gry St; Lendorf, Maria Elisabeth; Garred, Peter; Fyfe, Alexander; Paton, Robert S.; Thompson, Craig; Molsted, Stig; Kann, Caroline Elisabeth; Jensen, Claus Antonio; Hansen, Cecilie Bo; Løkkegaard, Ellen; Christensen, Thomas Broe; Simmonds, Peter; Fischer, Thea K.

In: Danish Medical Journal, Vol. 69, No. 5, A11210843, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Johannesen, CK, Martin, GS, Lendorf, ME, Garred, P, Fyfe, A, Paton, RS, Thompson, C, Molsted, S, Kann, CE, Jensen, CA, Hansen, CB, Løkkegaard, E, Christensen, TB, Simmonds, P & Fischer, TK 2022, 'Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers', Danish Medical Journal, vol. 69, no. 5, A11210843. <https://ugeskriftet.dk/dmj/prevalence-and-duration-anti-sars-cov-2-antibodies-healthcare-workers>

APA

Johannesen, C. K., Martin, G. S., Lendorf, M. E., Garred, P., Fyfe, A., Paton, R. S., Thompson, C., Molsted, S., Kann, C. E., Jensen, C. A., Hansen, C. B., Løkkegaard, E., Christensen, T. B., Simmonds, P., & Fischer, T. K. (2022). Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers. Danish Medical Journal, 69(5), [A11210843]. https://ugeskriftet.dk/dmj/prevalence-and-duration-anti-sars-cov-2-antibodies-healthcare-workers

Vancouver

Johannesen CK, Martin GS, Lendorf ME, Garred P, Fyfe A, Paton RS et al. Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers. Danish Medical Journal. 2022;69(5). A11210843.

Author

Johannesen, Caroline Klint ; Martin, Gry St ; Lendorf, Maria Elisabeth ; Garred, Peter ; Fyfe, Alexander ; Paton, Robert S. ; Thompson, Craig ; Molsted, Stig ; Kann, Caroline Elisabeth ; Jensen, Claus Antonio ; Hansen, Cecilie Bo ; Løkkegaard, Ellen ; Christensen, Thomas Broe ; Simmonds, Peter ; Fischer, Thea K. / Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers. In: Danish Medical Journal. 2022 ; Vol. 69, No. 5.

Bibtex

@article{fbbb9c1ea308436694ed0ba7b6fad9e2,

title = "Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers",

abstract = "Introduction. Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals. Methods. We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals. Results. SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%). Conclusion. Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.",

author = "Johannesen, {Caroline Klint} and Martin, {Gry St} and Lendorf, {Maria Elisabeth} and Peter Garred and Alexander Fyfe and Paton, {Robert S.} and Craig Thompson and Stig Molsted and Kann, {Caroline Elisabeth} and Jensen, {Claus Antonio} and Hansen, {Cecilie Bo} and Ellen L{\o}kkegaard and Christensen, {Thomas Broe} and Peter Simmonds and Fischer, {Thea K.}",

year = "2022",

language = "English",

volume = "69",

journal = "Danish Medical Journal",

issn = "2245-1919",

publisher = "Almindelige Danske Laegeforening",

number = "5",

}

RIS

TY - JOUR

T1 - Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers

AU - Johannesen, Caroline Klint

AU - Martin, Gry St

AU - Lendorf, Maria Elisabeth

AU - Garred, Peter

AU - Fyfe, Alexander

AU - Paton, Robert S.

AU - Thompson, Craig

AU - Molsted, Stig

AU - Kann, Caroline Elisabeth

AU - Jensen, Claus Antonio

AU - Hansen, Cecilie Bo

AU - Løkkegaard, Ellen

AU - Christensen, Thomas Broe

AU - Simmonds, Peter

AU - Fischer, Thea K.

PY - 2022

Y1 - 2022

N2 - Introduction. Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals. Methods. We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals. Results. SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%). Conclusion. Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.

AB - Introduction. Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals. Methods. We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals. Results. SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%). Conclusion. Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.

M3 - Journal article

C2 - 35485785

AN - SCOPUS:85129100901

VL - 69

JO - Danish Medical Journal

JF - Danish Medical Journal

SN - 2245-1919

IS - 5

M1 - A11210843

ER -

ID: 314061343

Department of Clinical Medicine